Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- Predictive value of early PSMA upregulation for the response to enzalutamide ±Nature cancer · 2026Trial
- Impact of Concomitant Hormone Therapy on the Diagnostic Performance ofThe Prostate · 2025Trial
- High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged withMolecular imaging · 2022Trial
- Does the addition of fentanyl premedication impact brown fat uptake in children undergoing a warming protocol for FDG PET?Pediatric radiology · 2025Article
- Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy.The oncologist · 2025Article
- The effect of androgen blockade on [EJNMMI research · 2025Article
- Modern Treatment of Skeletal Metastases: Multidisciplinarity and the Concept of Oligometastasis in the Recent Literature.Current oncology (Toronto, Ont.) · 2025Review
- Correlation of [European journal of nuclear medicine and molecular imaging · 2024Article
- Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Observational
- Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- CD38-Specific Gallium-68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?Theranostics · 2024Article
- Bench to Bedside Development of [Molecules (Basel, Switzerland) · 2023Review
- Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.European urology · 2023Article
- Quantitative [Scientific reports · 2023Article
- Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study.European journal of hybrid imaging · 2023Article
- Non-invasive PD-L1 quantification using [Journal for immunotherapy of cancer · 2023Article
- The significance of metabolic response to neoadjuvant androgen deprivation therapy detected with [European journal of nuclear medicine and molecular imaging · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PET with small molecules targeting prostate-specific membrane antigen (PSMA) is being adopted as a clinical standard for prostate cancer imaging. In this study, we evaluated changes in uptake on PSMA-targeted PET in men starting abiraterone or enzalutamide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.